Participated · Series A · Nov 2021

Vivoo ships at-home urine test strips that users scan with a mobile app; the app’s machine-learning image and color analysis returns instant, personalized wellness recommendations across about 15 tracked parameters. The company launched its subscription service in July 2020 and has amassed more than 50,000 users across over 100 countries in a little over a year. It offers one-time test packs and monthly or annual subscriptions (examples: $15.99/month for 3 months or $7.99/month on a 12-month plan). Vivoo says its urine tests are registered with the FDA while the app is positioned as a wellness data tool rather than a medical diagnostic. The startup plans a premium tier, additional test kits, and wearable integrations (e.g., Apple Watch) to cross-match sleep, activity, and heart data with urine metrics. Management says it expects revenue to grow 10x in 2021 and will spend roughly 20% of its budget on R&D, with third-party lab validation and future peer-reviewed publications planned.

Participated · Series B · Jul 2021

Prenexus Health produces certified-organic XOS (xylo-oligosaccharide) branded as PreneXOS™, a low-dose prebiotic ingredient that feeds beneficial probiotic bacteria in the gut microbiome in as little as one gram per day. The company uses a novel process to produce XOS from U.S.-grown organic sugar cane at its Gilbert, Arizona manufacturing facility. Proceeds from its recent financing will be used to significantly expand production capacity at that plant. Prenexus positions PreneXOS for use across supplement, food, beverage, and companion animal applications due to the ingredient's stability and low effective dose. The company emphasizes scientific development and clinical research as part of its product strategy. The announcement frames the financing as expansion capital to meet unprecedented demand for the ingredient.